Caribou Biosciences, Inc. Stock Price, News & Analysis

Caribou Biosciences (Nasdaq: CRBU) reported positive ANTLER Phase 1 data for allogeneic CAR-T therapy vispa-cel (CB-010) with confirmatory cohort (N=22) showing 82% ORR, 64% CR and 51% 12‑month PFS (efficacy cutoff Sep 29, 2025). An optimized-profile cohort (N=35) showed 86% ORR, 63% CR and 53% 12‑month PFS with median follow-up 11.8 months. Safety (safety cutoff Sep 2, 2025) across N=84 shows manageable events: thrombocytopenia 62%, CRS 55% (grade ≥3 <5%), no GvHD and no ≥grade 3 ICANS in key cohorts. Company plans a randomized pivotal Phase 3 (~250 patients) in 2L LBCL per FDA recommendation and held a webcast on Nov 3, 2025.

Caribou Biosciences (Nasdaq: CRBU) reported first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The 450x10^6 CAR-T cell dose is the recommended dose for expansion (RDE); dose expansion is planned to start by year-end with data expected in 2026. In 12 BCMA-naïve patients at the RDE (median follow-up 8.3 months) the trial showed 92% ORR, 75% ≥CR, and 91% MRD negativity (≤10^-5). Safety was described as manageable but included cytopenias, infections and isolated serious adverse events.

Caribou Biosciences (Nasdaq: CRBU) will host a live webcast at 8:00 am ET on Monday, November 3, 2025 to report new clinical data.

The presentation will cover updated results from the ANTLER Phase 1 trial of vispacabtagene regedleucel (vispa-cel; formerly CB-010) in relapsed or refractory B cell non-Hodgkin lymphoma and the first clinical data from the CaMMouflage Phase 1 trial of CB-011 in relapsed or refractory multiple myeloma. The company will also outline its anticipated pivotal Phase 3 trial design for vispa-cel and next steps for CB-011 development.

A live webcast is available on Caribou’s Events page and the archived webcast will be accessible for 30 days after the event.

Caribou Biosciences (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced its participation in the upcoming Citi 2025 Biopharma Back to School Conference. Rachel Haurwitz, PhD, the company's president and CEO, will engage in a fireside chat on September 3, 2025 at 2:30 PM EDT.

The presentation will be accessible through a webcast on Caribou's website's Events page and will remain available for at least 30 days following the event.

Caribou Biosciences (Nasdaq: CRBU) reported Q2 2025 financial results and provided updates on its clinical programs. The company ended Q2 with $183.9 million in cash, expected to fund operations into H2 2027. Key financial metrics include $2.7 million in licensing revenue and a GAAP net loss of $54.1 million ($0.58 per share).

Clinical highlights include completion of enrollment for both the CB-010 ANTLER Phase 1 trial in large B cell lymphoma and the dose escalation portion of the CB-011 CaMMouflage Phase 1 trial in multiple myeloma. The company plans to present robust datasets from both programs in H2 2025, with CB-010 showing potential outcomes comparable to approved autologous CAR-T cell therapies.

Caribou Biosciences (NASDAQ: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that its President and CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the Jefferies Global Healthcare Conference. The presentation is scheduled for June 4th at 9:20 AM EDT. The webcast will be accessible through Caribou's website and will remain available for at least 30 days following the event.

Caribou Biosciences (NASDAQ: CRBU) reported Q1 2025 financial results and provided updates on its clinical programs. The company ended Q1 with $212.5 million in cash and equivalents, expected to fund operations into H2 2027. Caribou reported a net loss of $40.0 million for Q1 2025.

The company recently implemented strategic pipeline prioritization, focusing on its lead oncology programs CB-010 and CB-011, while discontinuing other trials. This resulted in a 32% workforce reduction with estimated cash payments of $2.5-3.5 million.

Key upcoming milestones include two clinical datasets in H2 2025: CB-010's ANTLER trial data from a 20-patient cohort in large B cell lymphoma, and CB-011's CaMMouflage trial data from at least 25 multiple myeloma patients at multiple dose levels.

Caribou Biosciences (NASDAQ: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that its President and CEO, Rachel Haurwitz, PhD, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference. The presentation is scheduled for May 13th at 2:35 PM PDT. The webcast will be accessible through Caribou's website and will remain available for at least 30 days following the event.

Caribou Biosciences (CRBU) announced a strategic pipeline prioritization focusing on its lead oncology programs CB-010 and CB-011, with clinical data disclosures now planned for H2 2025. The company is implementing workforce and cost reduction initiatives, including a 32% workforce reduction, expected to extend cash runway into H2 2027.

Key updates include:

• CB-010 ANTLER trial: Plans to present data from 20-patient confirmatory cohort with 6+ months follow-up for 2L LBCL
• CB-011 CaMMouflage trial: Will share dose escalation data from minimum 25 patients with 3+ months follow-up for r/r MM
• Discontinuing GALLOP Phase 1 trial (CB-010 for lupus), AMpLify Phase 1 trial (CB-012 for AML), and preclinical research
• Reduction in force costs estimated at $2.5-3.5 million
• Preliminary cash position of $212.5 million as of March 31, 2025